Literature DB >> 18842532

Symptom management in hepatocellular carcinoma.

Virginia Chih-Yi Sun1, Linda Sarna.   

Abstract

Hepatocellular carcinoma (HCC) annually causes about one million deaths. Because of advanced stage at diagnosis, HCC carries a five-year survival rate of less than 5% in patients diagnosed with unresectable disease. Incidence for HCC is higher in men and individuals of Asian descent, where viral hepatitis, a leading cause of HCC, is endemic. This article will provide an overview of the complex symptom management of patients with HCC. The occurrence of multiple symptoms, including pain, fatigue, weight loss, and obstructive syndromes (e.g., ascites, jaundice) in patients with HCC is common. Because of limitations in the efficacy of current treatment options, aggressive symptom management is key to preserving physical functioning and quality of life in patients with HCC. A multidisciplinary team approach to symptom management of patients with HCC is critical, with oncology nurses playing an integral role.

Entities:  

Mesh:

Year:  2008        PMID: 18842532      PMCID: PMC2881685          DOI: 10.1188/08.CJON.759-766

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  52 in total

Review 1.  Symptom clusters: concept analysis and clinical implications for cancer nursing.

Authors:  Hee-Ju Kim; Deborah B McGuire; Lorraine Tulman; Andrea M Barsevick
Journal:  Cancer Nurs       Date:  2005 Jul-Aug       Impact factor: 2.592

Review 2.  Hepatocellular carcinoma presenting with obstructive jaundice.

Authors:  Eric C H Lai; Wan Yee Lau
Journal:  ANZ J Surg       Date:  2006-07       Impact factor: 1.872

Review 3.  Symptom control in palliative care--Part II: cachexia/anorexia and fatigue.

Authors:  Egidio Del Fabbro; Shalini Dalal; Eduardo Bruera
Journal:  J Palliat Med       Date:  2006-04       Impact factor: 2.947

4.  Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial.

Authors:  Eduardo Bruera; Vicente Valero; Larry Driver; Loren Shen; Jie Willey; Tao Zhang; J Lynn Palmer
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

5.  Selective internal radiation therapy with SIR-Spheres in patients with nonresectable liver tumors.

Authors:  Gabriele Pöpperl; Thomas Helmberger; Wolfgang Münzing; Rupert Schmid; Tobias Franz Jacobs; Klaus Tatsch
Journal:  Cancer Biother Radiopharm       Date:  2005-04       Impact factor: 3.099

6.  Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy.

Authors:  Paula Ravasco; Isabel Monteiro-Grillo; Pedro Marques Vidal; Maria Ermelinda Camilo
Journal:  J Clin Oncol       Date:  2005-01-31       Impact factor: 44.544

Review 7.  Prevention and treatment of cancer cachexia: new insights into an old problem.

Authors:  Maurizio Muscaritoli; Maurizio Bossola; Zaira Aversa; Rocco Bellantone; Filippo Rossi Fanelli
Journal:  Eur J Cancer       Date:  2005-11-28       Impact factor: 9.162

8.  Fatigue experiences in hepatocellular carcinoma patients during six weeks of stereotactic radiotherapy.

Authors:  Yeur-Hur Lai; Shiow-Ching Shun; Ya-Li Hsiao; Jeng-Fong Chiou; Lin-Lin Wei; Jo-Ting Tsai; Chung-Yu Kao
Journal:  Oncologist       Date:  2007-02

9.  Cancer statistics, 2007.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2007 Jan-Feb       Impact factor: 508.702

10.  Control of malignant ascites with spironolactone.

Authors:  B Greenway; P J Johnson; R Williams
Journal:  Br J Surg       Date:  1982-08       Impact factor: 6.939

View more
  28 in total

Review 1.  Palliative Care for People With Hepatocellular Carcinoma, and Specific Benefits for Older Adults.

Authors:  Christopher D Woodrell; Lissi Hansen; Thomas D Schiano; Nathan E Goldstein
Journal:  Clin Ther       Date:  2018-03-20       Impact factor: 3.393

2.  Important and relevant symptoms including pain concerns in hepatocellular carcinoma (HCC): a patient interview study.

Authors:  Karen Kaiser; Rajiv Mallick; Zeeshan Butt; Mary F Mulcahy; Al B Benson; David Cella
Journal:  Support Care Cancer       Date:  2013-11-21       Impact factor: 3.603

3.  Identification and validation of ferroptosis-associated gene-based on immune score as prognosis markers for hepatocellular carcinoma patients.

Authors:  Jukun Wang; Ke Han; Chao Zhang; Xin Chen; Yu Li; Linzhong Zhu; Tao Luo
Journal:  J Gastrointest Oncol       Date:  2021-10

4.  Integrated Analysis Reveals Critical Ferroptosis Regulators and FTL Contribute to Cancer Progression in Hepatocellular Carcinoma.

Authors:  Shaoying Ke; Congren Wang; Zijian Su; Shaoze Lin; Gongle Wu
Journal:  Front Genet       Date:  2022-05-16       Impact factor: 4.772

5.  HOXB9 promotes epithelial-to-mesenchymal transition via transforming growth factor-β1 pathway in hepatocellular carcinoma cells.

Authors:  Lin Sha; Lei Dong; Li Lv; Lizhi Bai; Xuening Ji
Journal:  Clin Exp Med       Date:  2014-08-01       Impact factor: 3.984

Review 6.  Epithelial-mesenchymal transition in hepatocellular carcinoma.

Authors:  Franziska van Zijl; Gudrun Zulehner; Michaela Petz; Doris Schneller; Christoph Kornauth; Mara Hau; Georg Machat; Markus Grubinger; Heidemarie Huber; Wolfgang Mikulits
Journal:  Future Oncol       Date:  2009-10       Impact factor: 3.404

7.  MiR-155 up-regulated by TGF-β promotes epithelial-mesenchymal transition, invasion and metastasis of human hepatocellular carcinoma cells in vitro.

Authors:  Da-Peng Li; Juan Fan; Yong-Jun Wu; Yu-Feng Xie; Juan-Min Zha; Xiu-Min Zhou
Journal:  Am J Transl Res       Date:  2017-06-15       Impact factor: 4.060

8.  Identification and analysis of circRNA-miRNA-mRNA regulatory network in hepatocellular carcinoma.

Authors:  Daxiang Zhou; Ling Dong; Lishan Yang; Qiang Ma; Feng Liu; Yanjie Li; Shu Xiong
Journal:  IET Syst Biol       Date:  2020-12       Impact factor: 1.615

9.  PDGF enhances IRES-mediated translation of Laminin B1 by cytoplasmic accumulation of La during epithelial to mesenchymal transition.

Authors:  Michaela Petz; Nicole C C Them; Heidemarie Huber; Wolfgang Mikulits
Journal:  Nucleic Acids Res       Date:  2012-08-16       Impact factor: 16.971

10.  The transcription factor GLI1 mediates TGFβ1 driven EMT in hepatocellular carcinoma via a SNAI1-dependent mechanism.

Authors:  Xin Zheng; Natalia B Rumie Vittar; Xiaohong Gai; Maite G Fernandez-Barrena; Catherine D Moser; Chunling Hu; Luciana L Almada; Angela L McCleary-Wheeler; Sherine F Elsawa; Anne M Vrabel; Abdirashid M Shire; Andrea Comba; Snorri S Thorgeirsson; Youngsoo Kim; Qingguang Liu; Martin E Fernandez-Zapico; Lewis R Roberts
Journal:  PLoS One       Date:  2012-11-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.